The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 6, 2003, Pages 517-528

  Christensen, Magnus ^a   Andersson, Katarina ^b   Dalén, Per ^b   Mirghani, Rajaa A ^b   Muirhead, Gary J ^b   Nordmark, Anna ^b   Tybring, Gunnel ^b   Wahlberg, Annell ^b   Yaşar, Ümit ^b   Bertilsson, Leif ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 3 HYDROXYQUININE; 5 HYDROXYOMEPRAZOLE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEBRISOQUINE; DRUG METABOLITE; LOSARTAN; OMEPRAZOLE; PARAXANTHINE; QUININE; UNCLASSIFIED DRUG; ISOENZYME;

ADULT; ARTICLE; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG POTENCY; DRUG URINE LEVEL; ENZYME ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL DISTRIBUTION; NORMAL HUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; URINALYSIS; BIOTRANSFORMATION; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; MIDDLE AGED; PHARMACOKINETICS; PHENOTYPE; TISSUE DISTRIBUTION;

ADULT; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMBINATIONS; FEMALE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PHARMACOKINETICS; PHENOTYPE; TISSUE DISTRIBUTION;

EID: 0038548118     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00050-X     Document Type: Article

References (41)

1. Breimer DD, Schellens JH. A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 1990;11:223-5.
2. Schellens JH, Janssens AR, van der Wart JH, van der Velde EA, Breimer DD. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach. Eur J Clin Invest 1989;19:472-9.
3. Schellens JH, van der Wart JH, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 1989;249:638-45.
4. Schellens JH, Soons PA, van der Wart JH, Hoevers JW, Breimer DD. Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man. Br J Clin Pharmacol 1991;31:175-8.
5. Schellens JH, Ghabrial H, van der Wart HH, Bakker EN, Wilkinson GR, Breimer DD. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 1991;50: 520-8.
6. Paolini M, Biagi GL, Bauer C, Cantelli-Forti G. Cocktail strategy: complications and limitations. J Clin Pharmacol 1993;33:1011-2.
7. Berthou F, Goasduff T, Lucas D, Dreano Y, Le Bot MH, Menez JF. Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 1995;5: 72-9.
8. Tenneze L, Verstuyft C, Becquemont L, Poirier JM, Wilkinson GR, Funck-Brentano C. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clin Pharmacol Ther 1999;66: 582-8.
9. Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith RL. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 1985;37:512-21.
10. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF, Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 1998;8:325-33.
11. Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, et al. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002;71:77-88.
12. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
13. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997;62: 365-76.
14. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail)". Clin Pharmacol Ther 2000;68: 375-83.
15. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, et al. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 2001; 70:455-61.
16. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10:187-216.
17. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
18. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
19. Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther 1998;79:55-87.
20. Neuhoff S, Langguth P, Dressler C, Andersson TB, Regardh CG, Spahn-Langguth H. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther 2000;38:168-79.
21. Yaşar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002;71:89-98.
22. Tybring G, Bottiger Y, Widen J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 1997;62:129-37.
23. Svensson JO, Bertilsson L. Rapid high-performance liquid Chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping. Pharmacogenetics 1999;9:529-31.
24. Mirghani RA, Ericsson O, Cook J, Yu P, Gustafsson LL. Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001;754:57-64.
25. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996; 6:159-76.
26. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity, a theoretical assessment. Pharmacogenetics 1996;6:121-49.
27. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-63.
28. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
29. Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther 1999;66:454-60.
30. Mirghani RA, Yaşar U, Zheng T, Cook JM, Gustafsson LL, Tybring G, et al. Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway. Drug Metab Dispos 2002;30: 1368-71.
31. Carrillo JA, Christensen M, Ramos SI, Aim C, Dahl ML, Benitez J, et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 2000;22:409-17.
32. Spigset O, Hagg S, Soderstrom E, Dahlqvist R. The paraxanthine: caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics 1999;9:409-12.
33. Hartter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, et al. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin Pharmacol Ther 2001;70: 10-6.
34. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38.
35. Yaşar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001;29:1051-6.
36. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547-51.
37. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjoqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992;51:12-7.
38. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
39. Zhao XJ, Yokoyama H, Chiba K, Wanwimolruk S, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther 1996;279:1327-34.
40. Wanwimolruk S, Paine MF, Pusek SN, Watkins PB. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4? Br J Clin Pharmacol 2002;54:643-51.
41. Spina E, Steiner E, Dumont E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators. Psychopharmacol Ser 1989;7:201-5.